Q1 FY27 results analysis · July 23, 2026

Dr Reddys Laboratories Ltd (DRREDDY) Q1 FY27 Results Analysis: PAT Plunges 69%, Gross Margin Compresses 1,039 bps

−68.7%PAT year on year, Rs. 443.50 Cr
Cofacto ResearchPublished July 23, 20262 min readNegative read
Quick summary

Dr Reddys Laboratories Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 8,070.50 Cr (-5.60% YoY) and PAT growth of -68.70% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 22, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 8,070.50 Cr (-5.60% YoY)
PAT (Q1)Rs. 443.50 Cr (-68.70% YoY)
EBITDA margin12.50% (-1420 bps YoY)
EPS (Q1)Rs. 5.32 (-68.70% YoY)
Market capRs. 97,348.47 Cr
CMPRs. 1,166.50

Quarter Snapshot

Dr. Reddy's Q1 FY27 results were sharply lower than the prior year, with revenue declining 5.6% YoY and PAT plunging 68.7%, dragged by lower lenalidomide sales and a Rs.239.7 Cr semaglutide provision. Gross margin compression of 1,039 bps and EBITDA margin of 12.5% (well below the 25% FY27 target) highlight significant earnings pressure. The company missed multiple guidance targets, and while the base business ex-lenalidomide grew double-digit, the near-term outlook remains challenging with the semaglutide supply halt and regulatory observations.

Key Investment Insights

Key Positives

  • India revenue grew 16.8% YoY, within the 15-16% sustainable guidance range.
  • Emerging Markets revenue grew 30.5% YoY, driven by new launches and favourable forex.
  • Europe revenue grew 13.3% YoY, supported by new generic launches.
  • Base business (excluding lenalidomide) delivered double-digit growth across all geographies per management.
  • Launched Bosutinib in the US with first-to-market 180-day exclusivity.
  • India secondary sales grew 14.6% (MQT) vs IPM 13.5%, indicating market share gain.

Risk Factors

  • Revenue declined 5.6% YoY and PAT plunged 68.7% YoY, driven by lower lenalidomide sales and a Rs.239.7 Cr semaglutide provision.
  • Gross margin compressed 1,039 bps YoY to 46.5%, and EBITDA margin fell 1,420 bps YoY to 12.5%.
  • SG&A expenses rose 12.4% YoY, missing the flat nominal guidance for FY27.
  • Operating cash flow was weak at Rs.101.5 Cr, only 23% of PAT, and free cash flow was negative Rs.215.8 Cr.
  • Borrowings increased 48% YoY to Rs.7,195.2 Cr, and the company received an FDA Form 483 with 7 observations at the Bachupally biologics facility.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.